James A.  Geraghty net worth and biography

James Geraghty Biography and Net Worth

James (Jim) Geraghty is an industry leader with over 30 years of strategic and leadership experience, centered around biotechnology companies developing and commercializing innovative therapies. Jim served as an entrepreneur in residence at Third Rock Ventures from 2013-2016. He was previously senior vice president, North America strategy and business development at Sanofi, which he joined upon its acquisition of Genzyme. Jim spent almost 20 years at Genzyme, where his roles included senior vice president of international development, president of Genzyme Europe, and founder, president and CEO of Genzyme Transgenics. Jim serves as chairman of the boards of Idera Pharma, Pieris Pharma, and Orchard Therapeutics, and on the board of Voyager Therapeutics. He started his career in healthcare strategy consulting at Bain and Company. A graduate of the Yale Law School, he holds a master’s degree from the University of Pennsylvania and a bachelor’s from Georgetown University.

What is James A. Geraghty's net worth?

The estimated net worth of James A. Geraghty is at least $861,783.00 as of June 28th, 2021. Mr. Geraghty owns 90,714 shares of Fulcrum Therapeutics stock worth more than $861,783 as of March 28th. This net worth evaluation does not reflect any other assets that Mr. Geraghty may own. Learn More about James A. Geraghty's net worth.

How do I contact James A. Geraghty?

The corporate mailing address for Mr. Geraghty and other Fulcrum Therapeutics executives is 26 LANDSDOWNE STREET, CAMBRIDGE MA, 02139. Fulcrum Therapeutics can also be reached via phone at (617) 651-8851 and via email at [email protected]. Learn More on James A. Geraghty's contact information.

Has James A. Geraghty been buying or selling shares of Fulcrum Therapeutics?

James A. Geraghty has not been actively trading shares of Fulcrum Therapeutics in the last ninety days. Most recently, on Monday, June 28th, James A. Geraghty bought 10,000 shares of Fulcrum Therapeutics stock. The stock was acquired at an average cost of $9.16 per share, with a total value of $91,600.00. Following the completion of the transaction, the director now directly owns 90,714 shares of the company's stock, valued at $830,940.24. Learn More on James A. Geraghty's trading history.

Who are Fulcrum Therapeutics' active insiders?

Fulcrum Therapeutics' insider roster includes James Geraghty (Director), Robert Gould (Insider), Christopher Morabito (Insider), Curtis Oltmans (SVP), and Peter Thomson (CEO). Learn More on Fulcrum Therapeutics' active insiders.

Are insiders buying or selling shares of Fulcrum Therapeutics?

During the last year, insiders at the sold shares 2 times. They sold a total of 5,094 shares worth more than $57,935.58. The most recent insider tranaction occured on March, 8th when VP Greg Tourangeau sold 4,884 shares worth more than $57,240.48. Insiders at Fulcrum Therapeutics own 2.5% of the company. Learn More about insider trades at Fulcrum Therapeutics.

Information on this page was last updated on 3/8/2024.

James A. Geraghty Insider Trading History at Fulcrum Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
6/28/2021Buy10,000$9.16$91,600.0090,714View SEC Filing Icon  
See Full Table

James A. Geraghty Buying and Selling Activity at Fulcrum Therapeutics

This chart shows James A Geraghty's buying and selling at Fulcrum Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Fulcrum Therapeutics Company Overview

Fulcrum Therapeutics logo
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial. The company is also discovering drug targets for the treatments of rare neuromuscular, muscular, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases. Fulcrum Therapeutics, Inc. has collaboration and license agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; and MyoKardia, Inc. to discover and develop therapies for the treatment of genetic cardiomyopathies. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Read More

Today's Range

Now: $9.50
Low: $9.26
High: $9.54

50 Day Range

MA: $9.22
Low: $6.70
High: $12.00

2 Week Range

Now: $9.50
Low: $2.25
High: $13.70

Volume

60,247 shs

Average Volume

684,544 shs

Market Capitalization

$588.43 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.31